ArticleOncology letters2026
Gliosarcoma of the right cerebellar hemisphere and parahippocampal region: A case report and literature review.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracranial gliosarcoma (GSM) is a rare and aggressive variant of glioblastoma, characterized by a dismal prognosis and high rates of early recurrence and metastasis. Preoperative differentiation from other neoplasms based on imaging features remains a significant clinical challenge. The current study reports the case of a 55-year-old female who presented with a headache as the primary clinical symptom. The patient underwent brain MRI due to progressively worsening symptoms of diplopia, intermittent dull headaches localized to the right occipital region and an unsteady gait. Preoperative magnetic resonance imaging revealed a large, lobulated mass in the right cerebellar hemisphere extending into the parahippocampal region. The diagnosis of WHO Grade IV GSM was confirmed by postoperative histopathological and immunohistochemical analysis, which revealed a biphasic pattern with glial fibrillary acidic protein-positive glial and smooth muscle actin/vimentin-positive sarcomatous components, alongside a high Ki-67 proliferation index of 30%. The patient underwent a subtotal resection followed by adjuvant radiotherapy with concurrent temozolomide chemotherapy. Despite this multimodal treatment, follow-up imaging demonstrated tumor recurrence at 2 months, with significant further progression and brain herniation observed at the 12-month follow-up. The present case underscores the diagnostic challenges and aggressive clinical course of GSM, particularly when located in the cerebellum. The rapid recurrence despite combined-modality therapy highlights the need for improved diagnostic strategies and more effective treatment protocols for this formidable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.